Objective:To investigate valsartan and atorvastatincalcium treatment on diabetic myocardial in-terstitial fibrosis effect and possible mechanism .,to provide theoretical basis for clinical medication .Methods :To diabetic rats as the research object ,which were randomly divided into :diabetes mellitus (DM ) group ,valsartan (Val) group ,atorvastatin (Ato) group ,combination (V + A)group and normal(CN) group .Intervention in 12 weeks ,the determination of hemodynamic parameters ,ventricular hypertrophy index ,detection of MMP2 gene ex-pression and protein activity in myocardial tissue .Results :Compared with DM group ,three hemodynamic index and ventricular hypertrophy index in treatment group reduced significantly (P < 0 .05) ,MMP2 mRNA was signifi-cantly descended (P < 0 .05) ,MMP2 protein activity reduced significantly (P < 0 .5) ,and two drugs combination of the above indicators to improve even more significant .Conclusion:Valsartan and Atorvastatin therapy candescend the myocardial tissue in diabetic cardiomyopathy in MMP 2 gene expression and protein activity ,its joint application has significant treatment effect .%目的：探讨糖尿病心肌病心室重构作用机制以及缬沙坦、阿托伐他汀治疗对糖尿病心肌心室重构影响。方法：STZ建立糖尿病大鼠模型，随机分为：糖尿病心肌病（DC）组、缬沙坦（Val）组、阿托伐他汀（Ato）组、联用（V＋A）组、正常（CN）组。干预12周，测定血流动力学参数、心脏质量（BW）、左心室质量（LVW）、检测心肌组织中MMP2基因表达以及MMP2蛋白含量及活性。结果：与DM 组相比，三个治疗组血流动力学指标及心室肥厚指标明显改善（P＜0．05），MMP2 mR-NA有明显减少（P＜0．05），MMP2蛋白含量及活性显著降低（P ＜0．5），而且两种药物联合治疗对上述指标改善更加显著。结论：缬沙坦和阿托伐他汀均可缓解糖尿病心肌病心室重构，其联合应用有协同治疗效果。其机制能与基质金属蛋白酶2的表达和活性调节有关。
展开▼
